NSCLC患者血清AIF-1、IL-6和VEGF水平异常变化及临床意义

承德医学院学报 ›› 2025, Vol. 42 ›› Issue (2): 100-106.

NSCLC患者血清AIF-1、IL-6和VEGF水平异常变化及临床意义

王玲玲¹, 姜浩², 朱金伶³, 刘瑞林⁴, 朱安军⁵, 耿学丽^1,*

1.承德医学院附属医院检验科,河北承德 067000;
2.承德市中心医院检验科,河北承德 067000;
3.河北省滦平县医院检验科,河北承德 067000;
4.平泉市医院检验科,河北承德 067000;
5.平泉市中医院心内科,河北承德 067000

收稿日期:2024-08-06 出版日期:2025-04-10 发布日期:2025-04-17
通讯作者: ^*
基金资助:
河北省政府资助临床医学优秀人才培养项目（ZF2024237）; 承德市科技计划项目（202204A073）

Abnormal Changes and Clinical Significance of Serum AIF-1, IL-6 and VEGF Levels in NSCLC Patients

WANG Ling-ling¹, JIANG Hao², ZHU Jin-ling³, LIU Rui-lin⁴, ZHU An-jun⁵, GENG Xue-li^1,*

1. Clinical Laboratory, The Affiliated Hospital of Chengde Medical University, Chengde, Hebei, 067000, China;
2. Clinical Laboratory of Chengde Central Hospital, Chengde, Hebei, 067000, China;
3. Clinical Laboratory of Luanping County Hospital, Chengde, Hebei, 067000, China;
4. Clinical Laboratory of Pingquan City Hospital, Chengde, Hebei, 067000, China;
5. Cardiology department, Pingquan Hospital of Traditional Chinese Medicine, Chengde, Hebei, 067000, China

Received:2024-08-06 Online:2025-04-10 Published:2025-04-17

摘要/Abstract

摘要： 目的研究同种异体移植炎症因子1（AIF-1）、白细胞介素6（IL-6）和血管内皮生长因子（VEGF）对非小细胞肺癌（NSCLC)诊断和预后评估的价值。方法选取183例NSCLC患者和120例健康体检者,分为NSCLC组和对照组,比较2组血清AIF-1、IL-6和VEGF的表达差异;分析其与CEA、SCCA、CYFRA21-1等肿瘤标志物及NSCLC临床病理特征的关系;应用受试者工作特征（ROC）曲线分析三者对NSCLC的诊断价值;分析血清AIF-1、IL-6、VEGF与生存的关系。结果 NSCLC患者血清AIF-1、IL-6、VEGF高于健康对照组（P<0.05）,与CEA、SCCA、CYFRA21-1呈正相关（P<0.05）;三者与淋巴结转移、远处转移、癌组织分化程度、TNM分期有关（P<0.05）,IL-6还与癌组织大小有关（P<0.05）;ROC曲线分析结果显示：三者联合检测,诊断NSCLC的敏感性为0.88,特异性为0.78,曲线下面积（AUC）为0.88,95% CI为0.84-0.92,优于单一指标;生存分析显示,AIF-1和IL-6高表达组的NSCLC患者总体生存率比低表达组低,差异有统计学意义（P<0.05）。结论 AIF-1、IL-6和VEGF参与了NSCLC的发生发展过程,有助于NSCLC的临床诊断和预后评估。

关键词: 非小细胞肺癌, 同种异体移植炎症因子1, 白细胞介素6, 血管内皮生长因子

Abstract: Objective To study the value of allograft inflammatory factor 1(AIF-1), interleukin-6(IL-6) and vascular endothelial growth factor(VEGF) in the diagnosis and prognosis assessment of non-small cell lung cancer(NSCLC). Methods A total of 183 NSCLC patients and 120 healthy subjects were selected.and divided into NSCLC group and control group The expression of serum AIF-1, IL-6 and VEGF were compared between the two groups. The relationship between them and tumor markers such as CEA, SCCA, CYFRA21-1 and clinicopathological features of NSCLC was analyzed. ROC curve was employed to analyze the diagnostic value of the three factors in NSCLC. The relationship between serum AIF-1, IL-6, VEGF and survival was analyzed. Results The serum levels of AIF-1, IL-6 and VEGF in NSCLC patients were higher than those in healthy controls (P<0.05), was positively correlated with CEA, SCCA and CYFRA21-1 (P<0.05). The three factors were related to lymph node metastasis, distant metastasis, tumor differentiation and TNM stage (P<0.05), IL-6 was also associated with cancer tissue size(P<0.05). ROC curve analysis showed that the sensitivity, specificity, area under the curve(AUC) and 95% CI of the three combined detection were 0.88, 0.78, 0.88, 0.84-0.92, respectively, which were better than those of single index. Survival analysis showed that the overall survival rate of NSCLC patients with high expression of AIF-1 and IL-6 was significantly lower than that with low expression of AIF-1 and IL-6 (P<0.05). Conclusion AIF-1, IL-6 and VEGF are involved in the occurrence and development of NSCLC, which are helpful for the clinical diagnosis and prognosis evaluation of NSCLC.

Key words: Non-small cell lung cancer, Allograft inflammatory factor 1, Interleukin-6, Vascular endothelial growth factor

中图分类号:

R734.2

王玲玲, 姜浩, 朱金伶, 刘瑞林, 朱安军, 耿学丽. NSCLC患者血清AIF-1、IL-6和VEGF水平异常变化及临床意义[J]. 承德医学院学报, 2025, 42(2): 100-106.

WANG Ling-ling, JIANG Hao, ZHU Jin-ling, LIU Rui-lin, ZHU An-jun, GENG Xue-li. Abnormal Changes and Clinical Significance of Serum AIF-1, IL-6 and VEGF Levels in NSCLC Patients[J]. Journal of Chengde Medical University, 2025, 42(2): 100-106.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: http://tougao.cdmc.edu.cn:8088/CN/

http://tougao.cdmc.edu.cn:8088/CN/Y2025/V42/I2/100

参考文献

[1] Oliver AL.Lung Cancer: Epidemiology and Screening[J]. Surg Clin North Am, 2022, 102(3): 335-344.
[2] Sung H, Ferlay J, Siegel RL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[3] Fan XX, Wu Q.Decoding Lung Cancer at Single-Cell Level[J]. Front Immunol, 2022, 13: 883758.
[4] Zhao K, Wang C, Shi F, et al.Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy[J]. BMC Cancer, 2021, 21(1): 66.
[5] Gao YH, Guan WJ, Liu Q, et al.Impact of COPD and emphysema on survival of patients with lung cancer: A meta-analysis of observational studies[J]. Respirology, 2016, 21(2): 269-279.
[6] Nalbandian A, Yan BS, Pichugin A, et al.Lung carcinogenesis induced by chronic tuberculosis infection: the experimental model and genetic control[J]. Oncogene, 2009, 28(17): 1928-1938.
[7] Liao KM, Hung CM, Shu CC, et al.Impact of Chronic Obstructive Pulmonary Disease on the Mortality of Patients with Small Cell Lung Cancer[J]. Int J Chron Obstruct Pulmon Dis, 2021, 16: 3255-3262.
[8] Utans U, Arceci RJ, Yamashita Y, et al.Cloning and characterization of allograft inflammatory factor-1: a novel macrophage factor identified in rat cardiac allografts with chronic rejection[J]. J Clin Invest, 1995, 95(6): 2954-2962.
[9] Diakos CI, Charles KA, McMillan DC, et al. Cancer-related inflammation and treatment effectiveness[J]. Lancet Oncol, 2014, 15(11): e493-e503.
[10] Winther-Larsen A, Aggerholm-Pedersen N, Sandfeld-Paulsen B.Inflammation scores as prognostic biomarkers in small cell lung cancer: a systematic review and meta-analysis[J]. Syst Rev, 2021, 10(1): 40.
[11] Liu CH, Chen Z, Chen K, et al.Lipopolysaccharide-Mediated Chronic Inflammation Promotes Tobacco Carcinogen-Induced Lung Cancer and Determines the Efficacy of Immunotherapy[J]. Cancer Res, 2021, 81(1): 144-157.
[12] Conway EM, Pikor LA, Kung SH, et al.Macrophages, Inflammation, and Lung Cancer[J]. Am J Respir Crit Care Med, 2016, 193(2): 116-130.
[13] Baranzini N, Monti L, Vanotti M, et al.AIF-1 and RNASET2 Play Complementary Roles in the Innate Immune Response of Medicinal Leech[J]. J Innate Immun, 2019, 11(2): 150-167.
[14] Maděrka Martin, Dvořák Vladimír, Hambálek Jozef, et al.Serum concentrations of S100-A11 and AIF-1 are elevated in cervical cancer patients with lymph node involvement[J]. Ceska Gynekol, 2021, 86(1): 17-21.
[15] Song JY, Bae HS, Koo do H, et al. Candidates for tumor markers of cervical cancer discovered by proteomic analysis[J]. J Korean Med Sci, 2012, 27(12): 1479-1485.
[16] Ye Y, Miao S, Lu R, et al.Allograft inflammatory factor-1 is an independent prognostic indicator that regulates β-catenin in gastric cancer[J]. Oncol Rep, 2014, 31(2): 828-834.
[17] Qu Z, Sun F, Zhou J, et al.Interleukin-6 Prevents the Initiation but Enhances the Progression of Lung Cancer[J]. Cancer Res, 2015, 75(16): 3209-3215.
[18] Chang CH, Hsiao CF, Yeh YM, et al.Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy[J]. Int J Cancer, 2013, 132(9): 1977-1985.
[19] Frezzetti D, Gallo M, Maiello MR, et al.VEGF as a potential target in lung cancer[J]. Expert Opin Ther Targets, 2017, 21(10): 959-966.
[20] Hwang I, Kim JW, Ylaya K, et al.Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients[J]. J Transl Med, 2020, 18(1): 443.